{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T11:58:44Z","timestamp":1791287924004,"version":"4.3.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020152","name":"Madrigal Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jhep.2026.03.021","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T07:51:21Z","timestamp":1774425081000},"page":"202-211","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4224-4703","authenticated-orcid":false,"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Bedossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4959-751X","authenticated-orcid":false,"given":"Cynthia D.","family":"Guy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Taub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Labriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul C.","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8535-2281","authenticated-orcid":false,"given":"Elaine","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yayun","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.03.021_bib1","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.021_bib2","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMra1503519","article-title":"Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis","volume":"377","author":"Diehl","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.03.021_bib3","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.jacc.2018.11.050","article-title":"Nonalcoholic fatty liver disease and the heart: JACC state-of-the-art review","volume":"73","author":"Stahl","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jhep.2026.03.021_bib4","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but No other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.03.021_bib5","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.021_bib6","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1016\/j.jhep.2017.07.027","article-title":"Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD","volume":"67","author":"Hagstrom","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.021_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.021_bib8","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.021_bib9","unstructured":"Food and Drug Administrationand Human Services. Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment. US Department of Health."},{"key":"10.1016\/j.jhep.2026.03.021_bib10","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/apt.15503","article-title":"Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials","volume":"50","author":"Pai","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.03.021_bib11","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4132\/jptm.2016.03.01","article-title":"Interobserver agreement on pathologic features of liver biopsy tissue in patients with nonalcoholic fatty liver disease","volume":"50","author":"Jung","year":"2016","journal-title":"J Pathol Transl Med"},{"key":"10.1016\/j.jhep.2026.03.021_bib12","first-page":"560","article-title":"Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations","volume":"11","author":"Younossi","year":"1998","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jhep.2026.03.021_bib13","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.jhep.2020.06.025","article-title":"Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials","volume":"73","author":"Davison","year":"2020","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.021_bib14","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jhep.2024.06.008","article-title":"Liver biopsy evaluation in MASH drug development: think thrice, act wise","volume":"81","author":"Harrison","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.021_bib15","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41575-023-00843-7","article-title":"Digital pathology for nonalcoholic steatohepatitis assessment","volume":"21","author":"Sanyal","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.021_bib16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jhep.2023.10.015","article-title":"Artificial intelligence-assisted digital pathology for non-alcoholic steatohepatitis: current status and future directions","volume":"80","author":"Ratziu","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.021_bib17","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.jhep.2014.02.015","article-title":"qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients","volume":"61","author":"Xu","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.021_bib18","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/hep.29090","article-title":"Dual-photon microscopy-based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis","volume":"65","author":"Wang","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.021_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199166","article-title":"Second harmonic generation microscopy provides accurate automated staging of liver fibrosis in patients with non-alcoholic fatty liver disease","volume":"13","author":"Chang","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2026.03.021_bib20","article-title":"An improved qFibrosis algorithm for precise screening and enrollment into non-alcoholic steatohepatitis (NASH) clinical trials","volume":"10","author":"Leow","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jhep.2026.03.021_bib21","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jhep.2022.06.018","article-title":"Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH","volume":"77","author":"Naoumov","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.021_bib22","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","article-title":"Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial","volume":"29","author":"Sanyal","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.03.021_bib23","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","article-title":"Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: results from the phase 2b TANDEM study","volume":"78","author":"Anstee","year":"2023","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.jhep.2026.03.021_bib24","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S2468-1253(24)00246-2","article-title":"Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial","volume":"9","author":"Loomba","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.021_bib25","doi-asserted-by":"crossref","DOI":"10.1177\/2632010X231162317","article-title":"Second-harmonic generated quantifiable fibrosis parameters provide signatures for disease progression and regression in nonalcoholic fatty liver disease","volume":"16","author":"Ng","year":"2023","journal-title":"Clin Pathol"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.021_bib26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.cgh.2025.06.042","article-title":"Repeatability and reproducibility of artificial imaging-based digital pathology for the evaluation of liver fibrosis","volume":"24","author":"Ren","year":"2026","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.021_bib27","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1111\/liv.16062","article-title":"Outcome prediction in metabolic dysfunction-associated steatotic liver disease using stain-free digital pathological assessment","volume":"44","author":"Kendall","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2026.03.021_bib28","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2026.03.021_bib29","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/hep.30986","article-title":"qFIBS: an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis","volume":"71","author":"Liu","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.021_bib30","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/S0168-8278(23)00540-8","article-title":"Digital pathology using stain-free imaging indices allows direct prediction of all-cause mortality, hepatic decompensation and hepatocellular carcinoma development in patients with non-alcoholic fatty liver disease","author":"Kendall","year":"2023","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.021_bib31","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.021_bib32","series-title":"Draft guidance for industry_noncirrhotic-nonalcoholic-steatohepatitis-with-liver-fibrosis-developing-drugs-for-treatment","year":"2018"},{"key":"10.1016\/j.jhep.2026.03.021_bib33","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/hep.28860","article-title":"Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood","volume":"65","author":"Decaris","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.021_bib34","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1021\/ac1032325","article-title":"Second harmonic generation imaging microscopy: applications to diseases diagnostics","volume":"83","author":"Campagnola","year":"2011","journal-title":"Anal Chem"},{"key":"10.1016\/j.jhep.2026.03.021_bib35","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2009.12.009","article-title":"Fibrillar collagen scoring by second harmonic microscopy: a new tool in the assessment of liver fibrosis","volume":"52","author":"Gailhouste","year":"2010","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.jhep.2026.03.021_bib36","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.cgh.2020.09.044","article-title":"Liver stiffness by magnetic resonance elastography predicts Q1 future cirrhosis, decompensation, and death in NAFLD","volume":"19","author":"Gidener","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.021_bib37","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2024.05.008","article-title":"Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD","volume":"81","author":"Gawrieh","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2026.03.021_bib38","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1053\/j.gastro.2022.06.073","article-title":"Liver stiffness on magnetic resonance elastography and the MEFIB index and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants","volume":"163","author":"Ajmera","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2026.03.021_bib39","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00004836-200310000-00014","article-title":"Is hypothyroidism a risk factor for non-alcoholic steatohepatitis?","volume":"37","author":"Liangpunsakul","year":"2003","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.jhep.2026.03.021_bib40","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s10620-011-2006-2","article-title":"Prevalence of hypothyroidism in nonalcoholic fatty liver disease","volume":"57","author":"Pagadala","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2026.03.021_bib41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cgh.2017.08.014","article-title":"Subclinical hypothyroidism and low-normal thyroid function are associated with nonalcoholic steatohepatitis and fibrosis","volume":"16","author":"Kim","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.021_bib42","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1016\/j.cgh.2018.11.024","article-title":"Low-normal thyroid function is associated with advanced fibrosis among adults in the United States","volume":"17","author":"Kim","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.021_bib43","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1007\/s10620-019-05687-3","article-title":"Low free triiodothyronine is associated with advanced fibrosis in patients at high risk for nonalcoholic steatohepatitis","volume":"64","author":"Manka","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2026.03.021_bib44","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1038\/s41591-023-02602-2","article-title":"An integrated gene-to-outcome multimodal database for metabolic dysfunction-associated steatotic liver disease","volume":"29","author":"Kendall","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2026.03.021_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0219764","article-title":"AEBP1 expression increases with severity of fibrosis in NASH and is regulated by glucose, palmitate, and miR-372-3p","volume":"14","author":"Gerhard","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2026.03.021_bib46","doi-asserted-by":"crossref","first-page":"5324","DOI":"10.1038\/s41467-022-33063-9","article-title":"Functional genomics uncovers the transcription factor BNC2 as required for myofibroblastic activation in fibrosis","volume":"13","author":"Bobowski-Gerard","year":"2022","journal-title":"Nat Commun"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001479?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001479?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:44:36Z","timestamp":1784133876000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826001479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0168827826001479"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.021","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}